Detalhe da pesquisa
1.
C3G, through its GEF activity, induces megakaryocytic differentiation and proplatelet formation.
Cell Commun Signal
; 16(1): 101, 2018 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30567575
2.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
J Clin Oncol
; 42(2): 205-217, 2024 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874957
3.
C3G transgenic mouse models with specific expression in platelets reveal a new role for C3G in platelet clotting through its GEF activity.
Biochim Biophys Acta
; 1823(8): 1366-77, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22659131
4.
C3G forms complexes with Bcr-Abl and p38α MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.
Cell Commun Signal
; 11(1): 9, 2013 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-23343344
5.
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.
J Immunother Cancer
; 9(6)2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34135100
6.
C3G contributes to platelet activation and aggregation by regulating major signaling pathways.
Signal Transduct Target Ther
; 5(1): 29, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32296045
7.
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Blood Cancer J
; 14(1): 83, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38760376
8.
C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis.
Oncotarget
; 8(67): 110994-111011, 2017 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29340032
9.
NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.
Clin Cancer Res
; 20(15): 4014-25, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24833663